Hypofractionated Radiotherapy

Researchers observed similar outcomes between hypofractionated and conventional radiation therapy among patients with alcohol- and tobacco-associated, locally advanced head and neck cancer, according to phase 3 study results.

Men who underwent hypofractionated radiotherapy after prostatectomy achieved comparable safety and quality-of-life outcomes as men who received a conventional regimen, according to study results.

Single-dose radiotherapy appeared safe and effective compared with hypofractionated stereotactic body radiotherapy among men with intermediate-risk prostate cancer, according to study findings published in JAMA Oncology.

Local hypofractionated stereotactic radiotherapy to the resection cavity demonstrated a favorable risk-benefit profile among patients with brain metastases, according to results of an international, multicenter cohort study.

Adjuvant whole-breast radiotherapy delivered in a five-fraction, once-weekly schedule appeared safe and effective for women with early breast cancer, according to 10-year results of the FAST trial published in Journal of Clinical Oncology.

An induction-concurrent chemotherapy sequence conferred a PFS benefit for patients with locoregionally advanced nasopharyngeal carcinoma treated with conventional fractionated radiotherapy, according to study results published in Cancer.

Moderate hypofractionated intensity-modulated radiation therapy produced long-term outcomes similar to those of conventionally fractionated IMRT among men with localized prostate cancer, according to a 10-year update of a randomized phase 3 trial.